Search Results - Ron A.A. Mathôt

  • Showing 1 - 17 results of 17
Refine Results
  1. 1

    Adoption of Machine Learning in Pharmacometrics: An Overview of Recent Implementations and Their Considerations by Alexander Janssen, Frank C. Bennis, Ron A. A. Mathôt

    Published in Pharmaceutics (2022-08-01)
    Get full text
    Article


  2. 2

    Target site antibiotic concentrations in orthopedic/trauma extremity surgery: is prophylactic cefazolin adequately dosed? A systematic review and meta-analysis by Fay R K Sanders, J Carel Goslings, Ron A A Mathôt, Tim Schepers

    Published in Acta Orthopaedica (2019-03-01)
    Get full text
    Article


  3. 3

    Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia by Trudy D. Buitenkamp, Ron A.A. Mathôt, Valerie de Haas, Rob Pieters, C. Michel Zwaan

    Published in Haematologica (2010-07-01)
    Get full text
    Article


  4. 4

    Application of SHAP values for inferring the optimal functional form of covariates in pharmacokinetic modeling by Alexander Janssen, Mark Hoogendoorn, Marjon H. Cnossen, Ron A. A. Mathôt, the OPTI‐CLOT Study Group and SYMPHONY Consortium

    Get full text
    Article


  5. 5

    Deep compartment models: A deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling by Alexander Janssen, Frank W. G. Leebeek, Marjon H. Cnossen, Ron A. A. Mathôt, the OPTI‐CLOT study group and SYMPHONY consortium

    Get full text
    Article


  6. 6

    Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis by Laura H. Bukkems, Siv Jönsson, Marjon H. Cnossen, Mats O. Karlsson, Ron A. A. Mathôt, the OPTI‐CLOT studies and the SYMPHONY consortium

    Get full text
    Article


  7. 7

    PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space by Michael E. Cloesmeijer, Erik Sjögren, Sjoerd F. Koopman, Peter. J. Lenting, Marjon H. Cnossen, Ron A. A. Mathôt, the OPTI‐CLOT study group and SYMPHONY consortium

    Get full text
    Article


  8. 8

    Pharmacokinetic/Pharmacodynamic Target Attainment of Ceftazidime in Adult Patients on General Wards with Different Degrees of Renal Function: A Prospective Observational Bicenter C... by Saskia E. Zieck, Suzanne L. de Vroom, Frouke Ph. Mulder, Gitte van Twillert, Ron A. A. Mathôt, Suzanne E. Geerlings, Reinier M. van Hest

    Published in Antibiotics (2023-02-01)
    Get full text
    Article


  9. 9

    Population Pharmacokinetics and Probability of Target Attainment of Different Dosing Regimens of Ceftazidime in Critically Ill Patients with a Proven or Suspected <i>Pseudomonas ae... by Annabel Werumeus Buning, Caspar J. Hodiamont, Natalia M. Lechner, Margriet Schokkin, Paul W. G. Elbers, Nicole P. Juffermans, Ron A. A. Mathôt, Menno D. de Jong, Reinier M. van Hest

    Published in Antibiotics (2021-05-01)
    Get full text
    Article


  10. 10

    Benzylpenicillin concentrations in umbilical cord blood and plasma of premature neonates following intrapartum doses for group B streptococcal prophylaxis by Amadou Samb, Thomas H. Dierikx, Yuma A. Bijleveld, Timo R. de Haan, Caspar J. Hodiamont, Elisabeth van Leeuwen, Anton H. L. C. van Kaam, Ron A. A. Mathôt, Douwe H. Visser

    Get full text
    Article


  11. 11

    Replacement therapy in pregnant women with von Willebrand disease during delivery: Factor levels and pharmacokinetics by Wala Al Arashi, Michael E. Cloesmeijer, Frank W. G. Leebeek, Johannes J. Duvekot, Marieke J. H. A. Kruip, Ron A. A. Mathôt, Marjon H. Cnossen, the OPTI‐CLOT/To WiN study group and SYMPHONY consortium

    Published in HemaSphere (2025-01-01)
    Get full text
    Article


  12. 12

    Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis by Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van derPlas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink

    Get full text
    Article


  13. 13

    Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-... by Lotte Haverman, Ron A A Mathôt, Floor Veltkamp, Djera H Khan, Christa Reefman, Susan Veissi, Hedy A van Oers, Elena Levtchenko, Sandrine Florquin, Joanna A E van Wijk, Michiel F Schreuder, Antonia H M Bouts

    Published in BMJ Open (2019-09-01)
    Get full text
    Article


  14. 14

    Rabies in humans: A treatment approach by Cornelis A. De Pijper, Pieter P.A.M. van Thiel, Diederik van de Beek, Matthijs C. Brouwer, Eleonora Aronica, Nicole P. Juffermans, Ron A.A. Mathôt, Corine H. GeurtsvanKessel, Janke Schinkel, Menno D. de Jong, Martin P. Grobusch, Abraham Goorhuis

    Published in Travel Medicine and Infectious Disease (2025-03-01)
    Get full text
    Article


  15. 15

    Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock—a two-centre randomised clinical t... by Luca F. Roggeveen, Tingjie Guo, Lucas M. Fleuren, Ronald Driessen, Patrick Thoral, Reinier M. van Hest, Ron A. A. Mathot, Eleonora L. Swart, Harm-Jan de Grooth, Bas van den Bogaard, Armand R. J. Girbes, Rob J. Bosman, Paul W. G. Elbers

    Published in Critical Care (2022-09-01)
    Get full text
    Article


  16. 16

    Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients by Sebastiaan D.T. Sassen, Ron A.A. Mathôt, Rob Pieters, Robin Q.H. Kloos, Valérie de Haas, Gertjan J.L. Kaspers, Cor van den Bos, Wim J.E. Tissing, Maroeska te Loo, Marc B. Bierings, Wouter J.W. Kollen, Christian M. Zwaan, Inge M. van der Sluis

    Published in Haematologica (2017-03-01)
    Get full text
    Article


  17. 17

    Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the... by Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek

    Published in Journal of Dermatological Treatment (2022-07-01)
    Get full text
    Article


Search Tools: